GLOW peptide and the FDA record
A cosmetic ingredient, a withdrawn nomination and a prescription answer three different questions. None is a substitute for the others.
FDA’s withdrawn-nomination entries
On FDA's page current as of April 22, 2026, BPC-157, TB-500 and GHK-Cu for injectable routes appear under “nominated but withdrawn”. They are no longer in Category 2. FDA's stated safety concerns remain in that record; withdrawal grants neither drug approval nor permission to compound.
For this question, the entry’s wording outweighs the reassuring sound of withdrawn. It describes what happened to a nomination. It does not say that the safety questions have been answered, and FDA publishes no date on which it moved these substances out of Category 2.
The GLOW blend itself is not FDA-approved. That fact remains separate from whether a clinician might prescribe and whether a pharmacy can lawfully prepare a particular medicine.
GLOW legal status and prescription access are separate questions
GLOW legal status depends on the three injected parts. Here is the rule in force today. For GLOW at Promise Peptides (mypromise.com), a licensed clinician in the U.S. must examine the request and decide on prescribing; some people are turned down.
A public FDA advisory meeting considered BPC-157 and TB-500 [14]. Pharmacy experts gave advice to the FDA. They discussed raw drug ingredients under the rule for one named patient [14]. The law calls this Section 503A. An advisory discussion does not establish permission to compound.
Prescription access and FDA drug approval are separate matters. The FDA lists BPC-157, TB-500 and injected GHK-Cu as 'nominated but withdrawn' after their sponsors took back the requests [12]. The FDA says these raw ingredients may cause serious harm. These parts are no longer in Category 2. Withdrawal does not grant FDA approval or permission to compound [12]. The service is for U.S. patients, and availability varies by state and treatment.
The meeting concerned the ingredients in the pharmacy mixing list. Compounded medicines do not have FDA approval.
The cream label belongs to another rule
Topical GHK-Cu may appear as Copper Tripeptide-1 on a cosmetic label. FDA’s cosmetic-versus-drug explanation describes why cosmetics generally do not require premarket FDA approval as drugs. A legal cosmetic ingredient is not thereby an approved injectable medicine.
The withdrawn-nomination entry for GHK-Cu specifically concerns injectable routes. BPC-157 and TB-500 have their own entries in the safety-risk table. I cannot read a skin-cream rule as permission for the complete injected blend.
A patient order and a pharmacy decision
The Section 503A framework concerns compounding for an identified patient with a valid prescription. Section 503B covers FDA-registered outsourcing facilities and a separate framework. A clinician's prescribing decision and a pharmacy's assessment of whether it may prepare and dispense are separate steps.
Raw ingredients need an applicable qualifying route: a recognized drug-quality monograph, use as a component of an approved drug, or inclusion on the relevant bulks list. Category 1 and Category 2 describe different positions under FDA's interim policy; Category 2 identifies substances with potential significant safety risks. A withdrawn nomination does not by itself establish eligibility.
The July 23-24, 2026 advisory-meeting calendar listed BPC-157 and TB-500 for consideration for the 503A bulks list. GHK-Cu was not on that agenda. An advisory discussion is not a final listing decision. The cited calendar does not supply an approval outcome, and I will not invent one from the fact that a meeting was listed.